“We'll see, though. But they run bigger antibody trials.…” — The a16z Show at 20:58
“We'll see, though. But they run bigger antibody trials. It's another relatively novelty-filled modality. They run bigger small molecule trials. They don't run bigger on everything, but they do run bigger in general. And this helps them to run trials that are more likely to succeed. We often have drugs that get…”
0:00
57:43